* Incyte Pharmaceuticals Inc., of Palo Alto, Calif., completed its acquisition of Hexagen plc, of Cambridge, U.K., announced last month. Incyte will pay $5 million in cash and issue 976,130 shares of Incyte common stock in exchange for all of Hexagen's outstanding capital stock. (See BioWorld Today, Aug. 17, 1998, p. 1.)
* Ribozyme Pharmaceuticals Inc., of Boulder, Colo., submitted an investigational new drug application (IND) to the FDA for Angiozyme, for the treatment of cancer. The drug is the first chemically synthesized ribozyme to be studied in clinical trials. It inhibits formation of the vascular endothelial growth factor receptor (VEGF-r), a key component in the angiogenesis pathway. If the IND is approved, the company will be the first to enter cliincal trials using the mechanism of VEGF-r down-regulation.